CSL · 13 hours ago
Principal Biostatician
CSL is a biotech company focused on accelerating innovation to deliver impactful therapies for patients. The Principal Biostatistician will play a crucial role in leading statistical strategies and methodologies for clinical trials and regulatory submissions, ensuring high-quality data analysis and reporting.
BiotechnologyHealth CareHealth DiagnosticsMedical
Responsibilities
Input to statistical strategy and ensure appropriate statistical methodologies applied to study design and data analysis for clinical trials and regulatory submissions
Lead components and fully support Biostatistics conduct in study design, protocol development, data collection, data analysis, reporting, and submission preparation
Author the initial statistical analysis plan for clinical trials and regulatory submissions. Be accountable for timely completion and quality of the statistical analysis plan
Support Biostatistics interactions with regulatory authorities (eg FDA, EMA, PMDA)
Be responsible for interpreting analysis results and ensuring reporting accuracy
Manage outsourcing operations or work with internal statistical programmers within the responsible projects. Ensure timeliness and quality of deliverables by CRO/FSP
Conduct reviews of deliverables to ensure quality
Be accountable for the TFL/CDISC package for study report and regulatory submission
Provide statistical thought partnership for innovative study design and clinical development plans, including Go-No Go criteria and probability of technical success calculations
Qualification
Required
PhD or MS in Biostatistics, Statistics
7+ years or relevant work experience
Experience with CROs (either managing a CRO, or having worked in a CRO)
Experience providing statistical leadership at a study level
Demonstrated statistical contribution in facilitating and optimizing clinical development
Company
CSL
CSL develops innovative biotherapies and influenza vaccines that save lives, and help people with life-threatening medical conditions.
Funding
Current Stage
Public CompanyTotal Funding
$111M2013-12-20Acquired
2004-02-06Post Ipo Equity· $111M
1994-06-03IPO
Recent News
Pharma Letter
2026-01-03
2025-10-29
Company data provided by crunchbase